



The Expanding Role of Advanced Imaging in Glioblastoma

Alexander Radbruch, MD, JD
Department of Neuroradiology
University of Heidelberg
Heidelberg, Germany





Advanced imaging techniques for...

- 1. Differential diagnosis**
- 2. Identification of pseudoprogression**
- 3. Identification of pseudoregression / T2-progress**


Advanced MRI for Differential Diagnosis: PCNSL vs GBM



Diffusion Imaging: PCNSL vs GBM




PCNSL: Low ADC
High Cellularity




GBM: High ADC
Lower Cellularity

DCE Perfusion




- T1 effect
- Assessment of the BBB (k_{trans})
- Scan time 4 - 10 min

DCE Perfusion







DSC Perfusion




- T1 effect
- Assessment of the BBB (k_{trans})
- Scan time 4 - 10 min

- T2* effect
- Assessment of CBV
- Scan time 1:30 min
- Correction techniques needed

DCE-Perfusion: PCNSL vs GBM





PCNSL: High k_{trans}
Severe Damage of BBB






GBM: Lower k_{trans}
moderate damage of BBB

DSC-Perfusion: PCNSL vs GBM





PCNSL: low CBV
low vascularity





GB: high CBV
high vascularity

DSC-Perfusion: PCNSL vs GBM



PCNSL

PCNSL: No
microbleeds
GBM: microbleeds




GBM

Advanced imaging techniques for...


- 1. Differential diagnosis**
- 2. Identification of pseudoprogression**
- 3. Identification of pseudoregression / T2-progress**

Pseudoprogression


Pre-
OP




Post-
OP



3 months post-
OP (standard
RCT)



6
months
post-OP



RANO-Criteria

JOURNAL OF CLINICAL ONCOLOGY

SPECIAL ARTICLE

From the Center for Neuro-Oncology,
Dana-Farber/Brown and Women's
Cancer Center; Division of Neurology,
Brigham and Women's Hospital; Depart-
ment of Radiology, Massachusetts
General Hospital; Brain Tumor Center,
Department of Neurology, Beth Israel
Deaconess Medical Center, Boston, MA;
Preston Robert Tisch Brain Tumor
Center, Duke University Medical Center,
Durham, NC; Mayo Clinic, Phoenix,

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

*Patrick Y. Wen, David R. Macdonald, David A. Reardon, Timothy F. Cloughesy, A. Gregory Sorensen,
Evanthia Galanis, John DeGroot, Wolfgang Wick, Mark R. Gilbert, Andrew B. Lassman, Christina Tsien,
Tom Mikkelsen, Eric T. Wong, Marc C. Chamberlain, Roger Stupp, Kathleen R. Lamborn,
Michael A. Vogelbaum, Martin J. van den Bent, and Susan M. Chang*

“within the first 12 weeks of completion of radiotherapy, progression can only be determined, if the majority of the new enhancement is outside of the radiation field”

Danger: Delay of the necessary change of therapy in the most aggressive tumors, that recur early

Differentiation with Diffusion and DSC Perfusion

Hypothesis Diffusion

- **True Progression:**
Increased Cellularity –
Decreased ADC
- **Pseudoprogression:**
Decreased Cellularity –
increased ADC

Hypothesis DSC Perfusion

- **True Progression:**
Increased vascularity –
Increased CBV
- **Pseudoprogression:**
decreased vascularity –
decreased CBV


Challenge: Postprocessing

Parametric Response Maps:


- Region of Interest Analysis does not reflect the heterogeneity of GBM
- Parametric Response Maps*: Voxelwise analysis of changes in ADC/CBV values

*Galban CJ, et al. *Nat Med.* 2009;15(5): 572–576.


Workflow: 1. Step



new enhancement at
3 months



baseline ADC






3 months ADC

1. ROI delineated on ce-T1 follow up

2. coregistration and transfer of ROI to ADC baseline and ADC f/u

3. calculation of rADC values by division of ROI with contralateral reference-ROI

Workflow: 2. Step



Voxelwise Subtraction of rADC values at baseline and follow up, presentation with scatter plot


Visualization on follow up ce-T1

Quantification of voxels




- 1) $r\text{ADC} (\text{baseline}) - r\text{ADC} (\text{follow up}) > 0.25$
- 2) $r\text{ADC} (\text{baseline}) - r\text{ADC} (\text{follow up}) < -0.25$

(Decrease of rADC)
(Increase of rADC)

Example:
Pseudo-
progression



Example:
True
Progression



Parametric Response Maps for DSC-Perfusion

VOLUME 28 • NUMBER 13 • MAY 1 2010

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Parametric Response Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma

Christina Tsien, Craig J. Galban, Thomas L. Chenevert, Timothy D. Johnson, Daniel A. Hamstra, Pia C. Sundgren, Larry Junck, Charles R. Meyer, Alnawaz Rehentulla, Theodore Lawrence, and Brian D. Ross

VOLUME 28 • NUMBER 29 • OCTOBER 10 2010

JOURNAL OF CLINICAL ONCOLOGY

CORRESPONDENCE

Perfusion Magnetic Resonance Imaging for Parametric Response Maps in Tumors: Is It Really That Easy?

reproducible at other sites with other magnetic resonance techniques or sequences.

CBV measured by MRI may be correlate with the tumor grade in patients with glioma, but only if the CBV is corrected for the outlined extravasation effects of the contrast agent.⁴ On the other hand, the

Findings:



- Decreased CBV – True Progression;
- Increased CBV - Pseudoprogression



Comment by Heiland et al:



- Correction techniques are needed for DSC Perfusion in case of a disrupted BBB
- Otherwise: Underestimation of CBV

Underestimation of CBV





- T1 and T2* effects are antagonistic
- If DCE is performed prior to DSC Perfusion – Interstitium is saturated
- Otherwise preload of contrast agent is needed prior to DSC Perfusion


Underestimation of CBV



- T1 and T2* effects are antagonistic
- If DCE is performed prior to DSC Perfusion – Interstitium is saturated
- Otherwise preload of contrast agent is needed prior to DSC Perfusion



Without correction
techniques



With correction
technique





Covarrubias, Rosen, Lev; The Oncologist 2004;9:528-537
“Dynamic Magnetic Resonance Perfusion Imaging of Brain Tumors”

Advanced imaging techniques for...





- 1. Differential diagnosis**
- 2. Identification of pseudoprogression**
- 3. Identification of pseudoregression / T2-progress**

Pseudoregression and SWI

Baseline:
Start of
Bevacizumab





Follow up 3
months
later:





A photograph of a sunset over a calm ocean. The sky is filled with warm, orange, and pink clouds. A bright, horizontal band of yellow light reflects off the water in the center of the frame, creating a path of light that leads towards the horizon. The overall atmosphere is peaceful and contemplative.

What is on the horizon?

Increased spatial Resolution: 7 Tesla





Volume Viewer

Conclusion

- Advanced imaging techniques
 - improve differential diagnosis of GBM
 - improve identification of pseudoprogression/pseudoregression
- Multiparametric approach is essential
- Standardization of Imaging parameters and multicenter studies are urgently needed

Thank you for your attention!